Safety and Tolerability of Difelikefalin for the Treatment of Moderate to Severe Pruritus in Hemodialysis Patients: Pooled Analysis From the Phase 3 Clinical Trial Program

RATIONALE & OBJECTIVE: We report a pooled safety analysis of intravenous difelikefalin in participants with moderate to severe chronic kidney disease–associated pruritus (CKD-aP) treated by hemodialysis in 4 phase 3 clinical studies. STUDY DESIGN: KALM-1 and KALM-2 were randomized, double-blind,...

Descripción completa

Detalles Bibliográficos
Autores principales: Fishbane, Steven, Wen, Warren, Munera, Catherine, Lin, Rong, Bagal, Sukirti, McCafferty, Kieran, Menzaghi, Frédérique, Goncalves, Joana
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2022
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9418597/
https://www.ncbi.nlm.nih.gov/pubmed/36039153
http://dx.doi.org/10.1016/j.xkme.2022.100513

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9418597/
https://www.ncbi.nlm.nih.gov/pubmed/36039153
http://dx.doi.org/10.1016/j.xkme.2022.100513

Ejemplares similares